Abstract
Caenorhabditis elegans is perhaps the best-understood metazoan in terms of cell fate, neural connectivity, nutrient sensing, and longevity. The study of this genetically amenable model has greatly accelerated progress in understanding human aging-associated diseases, such as diabetes and neurodegeneration. The nutrient-responsive cycling of OGlcNAc on key intracellular targets may play a key, yet unappreciated, role in human disease. Unlike their mammalian counterparts, loss-of-function mutants of ogt-1 (O-GlcNAc Transferase) and oga-1 (O-GlcNAcase) are viable in C. elegans, allowing the impact of the loss of O-GlcNAc cycling to be monitored in a living organism. C. elegans forward and reverse genetics, coupled with proteomics and chemical genomics, reveal networks of interactions and signaling pathways in which O-GlcNAc cycling may participate. The results point to a key regulatory role for O-GlcNAc cycling in cellular functions as diverse as nutrient uptake and salvage, cellular signaling, and transcription. The impact of altered O-GlcNAc cycling on the organism includes many of the hallmarks of aging-associated diseases: altered metabolism, lifespan, stress resistance, and immunity.
Current Signal Transduction Therapy
Title: C. elegans Genetic Networks Predict Roles for O-GlcNAc Cycling in Key Signaling Pathways
Volume: 5 Issue: 1
Author(s): Michelle A. Mondoux, Michael W. Krause and John A. Hanover
Affiliation:
Abstract: Caenorhabditis elegans is perhaps the best-understood metazoan in terms of cell fate, neural connectivity, nutrient sensing, and longevity. The study of this genetically amenable model has greatly accelerated progress in understanding human aging-associated diseases, such as diabetes and neurodegeneration. The nutrient-responsive cycling of OGlcNAc on key intracellular targets may play a key, yet unappreciated, role in human disease. Unlike their mammalian counterparts, loss-of-function mutants of ogt-1 (O-GlcNAc Transferase) and oga-1 (O-GlcNAcase) are viable in C. elegans, allowing the impact of the loss of O-GlcNAc cycling to be monitored in a living organism. C. elegans forward and reverse genetics, coupled with proteomics and chemical genomics, reveal networks of interactions and signaling pathways in which O-GlcNAc cycling may participate. The results point to a key regulatory role for O-GlcNAc cycling in cellular functions as diverse as nutrient uptake and salvage, cellular signaling, and transcription. The impact of altered O-GlcNAc cycling on the organism includes many of the hallmarks of aging-associated diseases: altered metabolism, lifespan, stress resistance, and immunity.
Export Options
About this article
Cite this article as:
Mondoux A. Michelle, Krause W. Michael and Hanover A. John, C. elegans Genetic Networks Predict Roles for O-GlcNAc Cycling in Key Signaling Pathways, Current Signal Transduction Therapy 2010; 5(1) . https://dx.doi.org/10.2174/157436210790226456
DOI https://dx.doi.org/10.2174/157436210790226456 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Anti-Inflammatory Responses of Resveratrol
Inflammation & Allergy - Drug Targets (Discontinued) Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors
Current Drug Safety Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets
Current Pharmaceutical Design The Impact of Uncontrolled Hypertension on the Longitudinal Systolic Function of the Left Ventricle
Current Hypertension Reviews Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Proteomic and Bioinformatic Analysis of Trypanosoma cruzi Chemotherapy and Potential Drug Targets: New Pieces for an Old Puzzle
Current Drug Targets ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Arterial Wall Structure and Dynamics in Type 2 Diabetes Mellitus Methodological Aspects and Pathophysiological Findings
Current Diabetes Reviews Chronic Heart Failure- Potential for Pharmacological Intervention
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Insights into Novel Coronavirus Disease 2019 (COVID-19): Current Understanding, Research, and Therapeutic Updates
Recent Patents on Biotechnology Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Inhibition of Early Upstream Events in Prodromal Alzheimer’s Disease by Use of Targeted Antioxidants
Current Aging Science Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry The Janus Face of Adenosine: Antiarrhythmic and Proarrhythmic Actions
Current Pharmaceutical Design Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy The Genetic Background of Cholesterol Gallstone Formation: An Inventory of Human Lithogenic Genes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders